Exclusion of Non-involved Uterus From the Target Volume in Locally Advanced Cervical Cancer

Launched by UNIVERSITY HOSPITAL, GHENT · May 18, 2018

Keywords

ClinConnect Summary

In our previous research we successfully implemented Intensity Modulate Arc Therapy with concurrent administration of cisplatin 40mg/m2 weekly (IMAT-C) in the multimodality treatment of Locally Advanced Cervical Cancer (LACC) . By delivering a higher biological dose to the tumor and lowering the dose to the Organs at Risk (OARs), toxicity significantly dropped and local control improved. However, there remains room for improvement for both toxicity and response to the treatment. Macroscopic tumor rest on hysterectomy reflects the existence of chemoradiation (CRT) resistant foci and correlat...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Biopsy proven carcinoma of the uterine cervix
• • locally advanced disease (FIGO IB2 or \>FIGO IIB or node positive) proven by clinical examination, 18-fluorodeoxyglucose positron emission tomography scan (18FDG PET-CT) and MRI
• • no more than 2 distant metastases (other than para-aortic lymph nodes);
• • WHO 0-2;
• • adequate kidney function for CRT, if inadequate kidney function radiotherapy can be the sole therapeutic regimen;
• • not pregnant or breastfeeding
• • absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; - willing and able to sign a written informed consent.
• Exclusion Criteria:
• • Patients unable to undergo MRI for any reason.